Other Potential Approaches for HER2-Mutant NSCLC Care

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss emerging treatment approaches and future directions in HER2-mutant non–small cell lung cancer. Dietrich highlights novel agents and combination strategies currently under investigation. Leal emphasizes the importance of learning from other oncogene-driven cancers, such as EGFR-mutant NSCLC, to refine sequencing and improve long-term patient outcomes.